# Varun Beverages (VARBEV)

CMP: ₹ 1003 Target: ₹ 1200 (20%)

Target Period: 12 months

months

May 4, 2021

# Recovery on fast track...

Varun Beverage (VBL) reported a strong set of results with 33.7% revenue growth led by 33% volume growth. However, consolidated organic volume growth was 24.7% in Q1CY21. The strong growth was led by low base quarter as well as a sharp recovery in out of home activity. Carbonated drinks, juices & water have been consumed largely 'on the go'. VBL sold 151 million cases during the quarter. Realisation per case improved slightly by 0.6% to 148 per case mainly on account of a change in product mix. Out of total volumes, 70% comprise carbonated drinks CSD, 7% juices & 23% water. Gross margins contracted 294 bps mainly due to change in product mix & sharp increase in PET resin prices. Operating profit increased 41% to ₹ 381 crore. With the 300 bps saving in employee spends & 77 bps savings in overhead spends, the company was able to improve its operating margins by 86 bps to 17%. PAT increased 127.7% to ₹ 136.8 crore. Adjusting for one-off spend in base quarter, PAT growth was 25.1%

#### Rural regions, at-home consumption to drive growth

VBL witnessed ~14% volume decline in CY20 due to lockdown however we are expecting a strong volume recovery 24.9% in CY21. The current summer season is also impacted by the second wave of Covid-19 and subsequent localised lockdown but the supply disruptions are limited this year. Moreover, the company has converted some 'out of home' consumption to 'at-home' by introducing 1.25 litre family pack. Further, with expanding distribution in rural regions, the company has seen strong growth in rural regions aided by establishment of Visi-coolers. Though, HORECA segment, which constitutes 10% of volumes, would continue to remain impacted, we believe rural regions and at-home consumption would drive growth for the company. We expect 20.4% revenue CAGR during CY20-22E.

#### PET resin, sugar prices to pressurise margins

With the increase in crude prices, PET resin prices have also gone up sharply in the last three months. Further, we expect sugar prices to increase ~15% in next one year. We believe these commodity prices would remain firm for a prolonged period of time, which would require certain amount of price hikes. However, we believe it would not be easy to take prices hikes given aggressive competition. Hence, we believe operating margins would remain under pressure. We expect 19.8%, 20.1% operating margins for CY021E, CY22E respectively (pre-Covid period margins were 20.3% in CY19).

#### Valuation & Outlook

Despite beverage being a discretionary category, the company has been able curtain the impact of pandemic and lockdown in CY20. Further, we believe increase at-home consumption would result in swift recovery in volumes in CY21E and we expect a full recovery in CY22E. With strong volume growth, robust operating margins & declining interest cost (with debt reduction), we expect net profit CAGR of 57.4% in CY20-22E. We value the stock at 20x CY22 EV/EBITDA with a target price of ₹ 1200/share (earlier target price ₹ 965) and revise our recommendation from HOLD to **BUY**.




BUY



Particulars	
Particulars (₹ crore)	Amount
Market Capitalization	29,301.8
Total Debt (CY20)	2,717.9
Cash & Investments (CY20)	104.6
EV	31,915.2
52 week H/L (₹)	1066 / 485
Equity capital	288.7
Face value	10.0

#### **Kev Risk**

- Any national lockdown could disrupt supply chain & demand for CSD in peak summer season
- Sustainable increase in crude based raw material prices & sugar prices could impact operating margins for prolonged period of time



#### Research Analyst

Sanjay Manyal sanjay.manyal@icicisecurities.com

Key Financial Summary						
Key Financials	CY18	CY19	CY20	CY21E	CY22E	CAGR (CY20-22E)
Net Sales	5105.3	7129.6	6450.1	7915.2	9357.7	20.4%
EBITDA	1006.6	1447.7	1201.9	1563.6	1885.4	25.2%
EBITDA Margin %	19.7	20.3	18.6	19.8	20.1	
Net Profit	299.9	472.2	362.1	612.6	897.3	57.4%
EPS (₹)	16.42	16.36	12.54	21.22	31.08	
P/E	61.1	61.3	80.0	47.3	32.3	
RoNW %	15.0	14.2	10.3	15.4	19.1	
RoCE (%)	14.2	15.5	10.9	17.4	23.4	

Exhibit 1: Variance Ar Particulars (₹ crore)	Q1CY21	Q1CY21	YoY (%)	0/CV21	QoQ (%)	Comments
raiuculais (< Clure)	UICIZI	UICIZI	101 (%)	UHUTZI		The strong revenue growth was led by robust volume growth of
Net Sales	2,240.9	1,676.4	33.7	1,330.9	68.4	24.7% & 1% realisation growth largely due to change in product mix
Raw Material Expenses	990.2	691.5	43.2	530.4	86.7	Gross margins contracted 300 bps on account of a change in product mix & sharp increase in PET resin prices
Employee Expenses	238.4	229.1	4.1	231.7	2.9	
Other operating Expenses	630.7	484.7	30.1	396.5	59.0	
EBITDA	381.6	271.2	40.7	172.2	121.6	
EBITDA Margin (%)	17.0	16.2	86 bps	12.9	409 bps	Operating margins improved 86 bps mainly due to saving in overhead spends
Depreciation	134.7	135.1	-0.3	134.7	0.0	
Interest	57.9	87.0	-33.4	62.0	-6.5	
Other Income	5.7	25.3	-77.3	5.6	2.9	
PBT	194.7	7.8	2,396.4	-18.9	-1,132.0	
Exceptional Items	0.0	66.5		0.0		
Tax Outgo	57.9	-52.3	-210.8	-11.6	-598.4	
PAT	136.8	60.1	127.7	-7.2	-1,988.5	Net profit increased 127.7% mainly on account of exceptional expense in base quarter. Adjusting for that, PAT increased 25.1%
Adj. PAT	136.8	109.3	25.1	-7.2	-1,988.5	

Source: Company, ICICI Direct Research

		CY21E			CY22E		
(₹ Crore)	Old	New	% Change	Old	New	% Change	Comments
Net Sales	7,695.6	7,915.2	2.9	8,448.5	9,357.7	10.8	We changed our CY22 estimates considering larger contribution from new products & full recovery from Covid related disruptions
EBITDA	1,553.6	1,563.6	0.6	1,715.8	1,885.4	9.9	
EBITDA Margin(%)	20.2	19.8	-43 bps	20.3	20.1	-16 bps	We changed our margin estimates due to rising sugar prices
PAT	605.1	612.6	1.2	763.6	897.3	17.5	
EPS (₹)	20.96	21.22	1.2	26.45	31.08	17.5	


Source: Company, ICICI Direct Research

Exhibit 3: Assumption	s								
			Current				Earl	ier	
Particulars (in million cases)	CY17	CY18	CY19E	CY20E	CY21E	CY22	CY21E	CY22	Comments
Carbonated Products	220.0	257.0	388.1	345.4	421.4	484.6	414.5	443.5	We factor in a full recovery from Covid-19 in CY22
% Growth	-1.3	16.8	51.0	-11.0	22.0	15.0	20.0	7.0	
Non Carbonated Products	14.0	22.0	29.7	22.3	29.0	34.7	26.3	27.9	
% growth	-11.1	57.1	35.0	-25.0	30.0	20.0	18.0	6.0	
Raw Material Cost									
Sugar	616.6	698.4	1,086.0	907.9	1,131.6	1,422.5	1,097.1	1,231.9	
% of sales	13.4	14.2	15.1	14.0	14.0	15.0	14.0	14.0	
cost/kg (₹)	38.9	37.0	36.6	34.8	36.9	40.2	36.5	38.4	Sugar prices are expected to increase by 10- 15% in the next one to two years

# Conference Call Highlights


- Revenue witnessed growth of 33.7% led by 33% volume growth and 0.8% realisation growth. The realisation growth was mainly on account of a change in product mix in favour of CSD. Consolidated organic volume growth was 24.7%
- Out of total volume, CSD contributed 70% to total volume compared to 67% in the corresponding quarter. Similarly, water segment contribution changed to 23% from 26% in the corresponding quarter. Juices contribution remained same at 7%
- The company witnessed small disruptions in supply chain due to localised lockdowns in April 2021. However, the situation is much better compared to last year due to better preparedness and higher volume contribution from rural regions (which are relatively insulated from lockdowns)
- In the last one year, out of home consumption has gone down from 40% to 20% given the company is trying to drive the at-home consumption with the introduction of 1.25 litre SKUs. However, HORECA segment continue to remain most impacted by lockdowns
- Capex related to Visi-coolers has already been done for CY21 as most Visi-Coolers have been placed before the summer season
- Energy drink 'sting' witnessed growth of 2.5x in CY20 over CY19. During Q1CY21, the company crossed sales of full year CY20
- In juices category, Tropicana has been growing steadily but the juice category still remains relatively small for VBL. Pathankot facility is nearing its full capacity. The company may have to take capacity expansion in the medium term
- On distribution side, the company would be able to utilise its CSD distribution network to drive growth in Tropicana. Moreover, south & west distribution network is less than 50% of the targeted area. The company would take two to three years to reach the distribution at optimum level
- The consumption pattern has been changed with SKU upgradation from 500 ml to 1.0 litre
- Capax for the next two years would be closer to depreciation provisioning given the company is not undertaking any major capacity expansion
- Prices of PET resins have significantly gone up in last three months. However, the company has sufficient inventory to cover the entire summer season in 2021. Sugar prices during the quarter have remained stable
- Income tax rate for full year would be 25-26%

# **Key Metrics**



Source: Company, ICICI Direct Research


### Exhibit 5: Volume growth to drive growth



■ Volume growth ■ Realisation growth


Source: Company, ICICI Direct Research

### Exhibit 6: Raw material to sales & EBITDA margins (%)




Source: Company, ICICI Direct Research

#### Exhibit 7: EBITDA (₹ crore) & EBITDA growth (%) trend




Source: Company, ICICI Direct Research

#### Exhibit 8: Earnings to grow on low base in CY21E (₹ crore)



Source: Company, ICICI Direct Research

#### Exhibit 9: Return ratio trend (%)



Source: Company, ICICI Direct Research

Exhibit 10:	Valuation								
	Sales	Growth	EPS	Growth	PE	EV/EBITDA	RoNW	RoCE	
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)	
CY19	7129.6	39.7	16.4	-0.4	61.3	21.9	14.2	15.5	
CY20	6450.1	-9.5	12.5	-23.3	80.0	26.3	10.3	10.9	
CY21E	7915.2	22.7	21.2	69.2	47.3	19.6	15.4	17.4	
CY22E	9357.7	18.2	31.1	46.5	32.3	15.7	19.1	23.4	

# Financial summary

Exhibit 11: Profit and los	ss statem	ent		₹ crore
	CY19	CY20	CY21E	CY22E
Total operating Income	7129.6	6450.1	7915.2	9357.7
Growth (%)	39.7	-9.5	22.7	18.2
Raw Material Expenses	3219.4	2763.9	3455.5	4159.0
Employee Expenses	810.8	889.7	1029.0	1197.8
Marketing Expenses	122.1	0.0	121.3	141.8
Other expenses	1529.6	1594.6	1745.8	1973.7
Total Operating Expenditure	5681.9	5248.3	6351.6	7472.3
EBITDA	1,447.7	1,201.9	1,563.6	1,885.4
Growth (%)	43.8	-17.0	30.1	20.6
Depreciation	488.6	528.7	555.5	580.3
Interest	309.6	281.1	249.5	145.0
Other Income	42.5	37.0	40.5	44.6
PBT	691.9	429.0	799.2	1204.7
Total Tax	224.1	5.2	191.8	313.2
Minority interest	0.0	0.0	0.0	0.0
Profit from Associates	4.4	4.8	5.3	5.8
PAT	472.2	428.6	612.6	897.3
Growth (%)	57.5	-23.3	69.2	46.5
EPS (₹)	16.4	12.5	21.2	31.1

Source: Company, ICICI Direct Research

Exhibit 12: Cash flow statement											
(Year-end March)	CY19	CY20	CY21E	CY22E							
Profit After Tax	907.7	599.6	856.8	1,036.5							
Add: Depreciation	482.6	523.2	555.5	580.3							
(Inc)/dec in Current Assets	-319.3	-98.6	174.7	-259.7							
Inc/(dec) in CL and Provisions	234.1	-12.3	197.0	354.4							
CF from operating activities	1,305.2	1,012.0	1,784.0	1,711.5							
(Inc)/dec in Investments	73.1	107.4	0.0	0.0							
(Inc)/dec in LT loans & advances	0.0	0.0	0.0	0.0							
(Inc)/dec in Fixed Assets	-2,358.2	-535.6	-386.1	-429.3							
Others	22.1	8.7	0.0	0.0							
CF from investing activities	-2,319.2	-471.1	-386.1	-429.3							
Issue/(Buy back) of Equity	900.2	0.0	0.0	0.0							
Inc/(dec) in loan funds	648.7	-470.9	-900.0	-1,000.0							
Dividend paid & dividend tax	-78.2	-72.2	-153.2	-179.5							
Others	-317.5	-277.4	-249.5	-145.0							
CF from financing activities	1,109.7	-573.7	-1,345.9	-1,301.8							
Net Cash flow	95.7	-32.8	52.0	-19.6							
Opening Cash	106.9	138.0	104.6	156.6							
Other Bank balance	33.1	85.5	85.5	85.5							
Closing Cash	171.1	104.6	156.6	137.0							

Source: Company, ICICI Direct Research

Exhibit 13: Balance shee	et			₹ crore
(Year-end March)	CY19	CY20	CY21E	CY22E
Liabilities				
Equity Capital	288.7	288.7	288.7	288.7
Reserve and Surplus	3039.7	3235.3	3694.8	4412.6
Total Shareholders funds	3328.4	3524.0	3983.5	4701.3
LT Borrowings & Provisions	2355.4	2004.1	1204.1	304.1
Deferred Tax Liability	282.5	225.9	237.2	249.1
Total Liabilities	6168.1	6023.4	5639.6	5480.1
Assets				
Gross Block	7,710.6	8,542.5	8,959.4	9,359.4
Less: Acc Depreciation	2,186.7	2,715.4	3,270.8	3,851.1
Net Block	5,892.5	5,827.2	5,688.5	5,508.2
Capital WIP	63.8	66.8	50.0	50.0
Net Intangible Assets	562.3	557.2	585.1	614.3
Non-current Investments	0.9	0.1	0.1	0.1
Goodwill	24.2	24.2	24.2	24.2
Current Assets				
Inventory	881.5	928.8	769.5	909.8
Debtors	172.6	241.8	197.9	233.9
Loans and Advances	6.9	10.0	219.9	259.9
Other Current Assets	219.8	251.8	17.6	20.8
Cash	138.0	104.6	156.6	137.0
Deferred Tax Assests	12.8	11.0	11.0	11.0
Current Liabilities				
Creditors	477.7	511.4	527.7	623.8
Provisions	30.0	33.2	66.0	78.0
Short term debt & other CL	1,697.5	1,886.5	1,933.0	2,073.5
Application of Funds	6,168.1	6,023.4	5,639.6	5,480.1

Source: Company, ICICI Direct Research

Exhibit 14: Key ratios				₹ crore
(Year-end March)	CY19	CY20	CY21E	CY22E
Per share data (₹)				
EPS	16.4	12.5	21.2	31.1
Cash EPS	33.3	30.9	40.5	51.2
BV	115.3	122.1	138.0	162.9
DPS	0.0	2.5	5.3	6.2
Cash Per Share	75.7	94.1	113.3	133.4
Operating Ratios (%)				
EBITDA Margin	20.3	18.6	19.8	20.1
PBT / Total Operating income	9.7	5.6	10.1	12.9
PAT Margin	6.6	5.6	7.7	9.6
Inventory days	45.1	52.6	35.5	35.5
Debtor days	8.8	13.7	9.1	9.1
Creditor days	24.5	28.9	24.3	24.3
Return Ratios (%)				
RoE	14.2	10.3	15.4	19.1
RoCE	15.5	10.9	17.4	23.4
Valuation Ratios (x)				
P/E	61.3	80.0	47.3	32.3
EV / EBITDA	21.9	26.3	19.6	15.7
EV / Net Sales	4.4	4.9	3.9	3.2
Market Cap / Sales	4.1	4.5	3.7	3.1
Price to Book Value	8.7	8.2	7.3	6.2
Solvency Ratios				
Debt/EBITDA	1.9	2.3	1.2	0.4
Debt / Equity	0.8	0.8	0.5	0.2
Current Ratio	0.6	0.7	0.6	0.6
Quick Ratio	0.1	0.2	0.2	0.2

	CMP	TP		M Cap		EPS (₹) P/E (x)				Price/Sales (x)			F	OCE (%	)	RoE (%)			
	(₹)	(₹)	Rating	(₹ Cr)	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Colgate (COLPAL)	1,491	1,860	Buy	43,654	35.0	37.8	40.5	42.5	39.4	36.8	9.3	8.5	8.0	76.7	80.2	83.7	58.7	61.5	64.3
Dabur India (DABIND)	537	620	Buy	91,067	9.9	11.0	12.3	54.2	48.8	43.8	9.4	8.5	7.7	26.5	27.0	27.4	22.9	23.0	23.3
Hindustan Unilever (HINLEV)	2,407	2,715	Buy	554,458	33.9	40.5	45.0	71.1	59.4	53.4	12.2	10.6	9.8	18.9	25.6	27.7	17.1	20.0	21.6
ITC Limited (ITC)	200	245	Hold	267,970	10.7	12.8	14.1	18.7	15.6	14.1	5.8	5.1	4.7	26.3	31.0	33.1	20.1	23.7	25.3
Jyothy Lab (JYOLAB)	142	175	Hold	5,728	5.9	6.4	7.1	24.2	22.2	20.0	3.1	2.8	2.6	30.6	31.1	31.6	26.0	25.9	26.3
Marico (MARLIM)	460	490	Buy	53,027	9.3	9.6	10.7	49.5	47.8	43.0	6.6	5.9	5.3	40.3	42.5	45.5	37.0	37.4	39.7
Nestle (NESIND)	16,546	19,300	Hold	164,840	216.0	254.8	283.8	76.6	64.9	58.3	12.4	11.2	10.2	54.6	62.7	69.1	103.1	124.2	142.1
Tata Consumer Products (TAT	645	700	Buy	53,448	11.0	12.5	14.1	58.5	51.7	45.7	4.6	4.3	4.0	8.9	9.8	10.5	7.2	8.1	8.8
VST Industries (VSTIND)	3,191	3,600	Hold	5,090	201.3	218.8	234.9	15.9	14.6	13.6	4.6	4.2	3.9	43.4	45.6	48.2	33.0	33.9	36.1
Varun Beverage (VARBEV)	1,003	1,200	Buy	28,955	12.5	21.2	31.1	80.0	47.3	32.3	4.5	3.7	3.1	10.9	17.4	23.4	10.3	15.4	19.1
Zydus Wellness (ZYDWEL)	2,072	2,500	Buy	12,343	19.0	60.3	71.3	109.2	34.4	29.0	6.6	5.8	5.3	6.2	7.8	9.0	5.5	8.0	9.3

## **RATING RATIONALE**

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

#### ANALYST CERTIFICATION

I/We, Sanjay Manyal (MBA Finance) Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory

Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number –

INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its

various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect

of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavor to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.